CatalystFDA/Bio

TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS

Phase 3 success on co-primary and all key secondary endpoints signals strong efficacy data.

What changed

Phase 3 success on co-primary and all key secondary endpoints signals strong efficacy data.

Why it matters

Phase 3 success on co-primary and all key secondary endpoints signals strong efficacy data. — impact context not separately stored; see What changed.

Sources